Understanding CD47 in Rheumatoid Arthritis
Role of the CD47 Pathway in Rheumatoid Arthritis Pathogenesis and Treatment
['FUNDING_R01'] · UNIVERSITY OF ROCHESTER · NIH-11143857
This research explores how a specific signal called CD47 contributes to rheumatoid arthritis and if blocking it could offer new ways to treat the condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11143857 on ClinicalTrials.gov |
What this research studies
Rheumatoid arthritis can cause ongoing pain and damage, especially to joints and bones, and current treatments don't always address all aspects of the disease. This project looks at a specific biological signal, CD47, which might play a role in both inflammation and bone damage. Researchers will examine patient samples and use mouse models to understand how CD47 works in arthritis. They also plan to test if blocking CD47, possibly in combination with existing treatments, could help reduce inflammation and prevent bone erosion.
Who could benefit from this research
Good fit: Patients living with rheumatoid arthritis, particularly those whose current treatments do not fully address their inflammation, joint damage, or bone erosion, are the focus of this research.
Not a fit: Patients without rheumatoid arthritis or those whose condition is well-managed by existing therapies may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that better target the underlying causes of rheumatoid arthritis, including bone damage and fibroblast issues, offering more complete relief for patients.
How similar studies have performed: While current therapies improve inflammation, this approach explores a novel pathway to address fibroblast and bone pathology in rheumatoid arthritis, areas where effective treatments are currently lacking.
Where this research is happening
ROCHESTER, UNITED STATES
- UNIVERSITY OF ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KORMAN, BENJAMIN DOUGLAS — UNIVERSITY OF ROCHESTER
- Study coordinator: KORMAN, BENJAMIN DOUGLAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.